Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Baxter
Colorcon
Johnson and Johnson
Express Scripts

Last Updated: January 25, 2020

DrugPatentWatch Database Preview

Litigation Details for CyDex Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

CyDex Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)

Docket   Start Trial Date Filed 2017-12-20
Court District Court, D. Delaware Date Terminated 2019-11-06
Cause 35:271 Patent Infringement Assigned To Leonard Philip Stark
Jury Demand None Referred To
Parties ACTAVIS LLC; CYDEX PHARMACEUTICALS, INC.; TEVA PHARMACEUTICAL INDUSTRIES LTD.; TEVA PHARMACEUTICALS USA, INC.
Patents 8,410,077; 9,200,088; 9,493,582
Attorneys Alison M. Heydorn; Charles B. Klein; David M. Fry; Eimeric Reig-Plessis; George C. Lombardi; Jack B. Blumenfeld; Jeremy A. Tigan; Karen Elizabeth Keller; Kevin E. Warner; Ryan B. Hauer; Samuel S. Park
Firms Morris, Nichols, Arsht & Tunnell; Shaw Keller LLP
Link to Docket External link to docket
Small Molecule Drugs cited in CyDex Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for CyDex Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 1 and lawfully issued United States Patent No. 8,410,077 (“the ’077 patent”), entitled “Sulfoalkyl Ether …such patents to this lawsuit. COUNT I FOR INFRINGEMENT OF U.S. PATENT NO. 8,410,077 …“Notification of Certification for U.S. Patent Nos. 8,410,077; 9,200,088; and 9,493,582 Pursuant to §…interest in the ’077 patent, the ’088 patent, and the ’582 patent (collectively, “the patents-in-suit”). … 1. This is an action for patent infringement under the patent laws of the United States arising External link to document
2019-11-06 116 SO ORDERED quot;) for infringement of United States Patent Nos. 8,410,077, 9,200,088, and 9,493 ,582 (…JUDGMENT AND DISMISSAL ORDER This action for patent infringement (the "Litigation") has been… (collectively, the "CyDex Patents"). CyDex' s commencement of the Litigation… § 355U)(2)(A)(vii)(IV) directed to the CyDex Patents and seeking approval to market a generic melphalan…injection prior to the expiration of the CyDex Patents. CyDex and Teva have agreed to enter into External link to document
0000-00-00 4 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,410,077 B2; 9,200,088 B2; 9,493,582…2017 6 November 2019 1:17-cv-01832 835 Patent - Abbreviated New Drug Application(ANDA) External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Boehringer Ingelheim
Moodys
Dow
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.